NEW YORK, Oct. 6 (GenomeWeb News) - Epoch Biosciences said today that it has terminated an arrangement under which its MGB Eclipse genetic analysis probe systems was distributed by Amersham Biosciences.
According to Epoch, the deal was ended because of Amersham's failure to meet contractually established sales goals for the system. In August, the company disclosed that it anticipated revenues from Amersham would be insignificant for the rest of the year and that its projected revenues for the full-year 2003 would be between $8.5 million and $9.5 million. Epoch said that this guidance remains unchanged.
Epoch CEO William Gerber said in a statement that the company is in discussions with other potential distribution partners for the MGB Eclipse product line.